OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
November 07, 2007
Equipped with a new sourcing strategy in Asia and improving market conditions, Pfizer CentreSource expects a good performance from its steroid business this year and in 2008.
November 02, 2007
The US Food and Drug Administration launched a new program on Oct. 4 to increase the number and variety of generic drugs available to the public, beginning in fiscal year 2008. The Generic Initiative for Value and Efficiency (GIVE) will use existing resources to help the agency "modernize and streamline the generic drug approval process," according to FDA.
Candid comments from a Big Pharma executive highlight the complexity of contract manufacturing.
News and Views
November 01, 2007
Pharmaceutical manufacturers are under increasing pressure to shorten time-to-market, produce treatments with unpredictable product lifetimes, provide greater flexibility and, at the same time, comply with ever more stringent quality, validation, stability and traceability constraints. While this is encouraging for the contract manufacturing sector, it creates the need for even greater manufacturing flexibility.
Company Notes: Gibraltar expands facilities; Allozyne appoints new president and CEO, more.
October 24, 2007
Company and People Notes: ImClone, BMS, and Merck form agreement; CRI Worldwide names new CEO, more.
October 18, 2007
Company and People Notes: Orexo acquires Biolipox, Avalon cofounder resigns, more...
October 11, 2007
Company and People Notes: Novartis and MIT to study continuous processing, GSK appoints Andrew Witty as CEO, more.
October 05, 2007
Company and People Notes: Thermo Fisher Scientific buys Priority Solutions International, Wyeth elects new president and CEO, more.